197 related articles for article (PubMed ID: 10720512)
1. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
Harrigan PR; Stone C; Griffin P; Nájera I; Bloor S; Kemp S; Tisdale M; Larder B
J Infect Dis; 2000 Mar; 181(3):912-20. PubMed ID: 10720512
[TBL] [Abstract][Full Text] [Related]
2. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S;
Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
[TBL] [Abstract][Full Text] [Related]
4. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
[TBL] [Abstract][Full Text] [Related]
5. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
Lanier ER; Givens N; Stone C; Griffin P; Gibb D; Walker S; Tisdale M; Irlbeck D; Underwood M; St Clair M; Ait-Khaled M
HIV Med; 2004 Nov; 5(6):394-9. PubMed ID: 15544690
[TBL] [Abstract][Full Text] [Related]
6. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG
Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485
[TBL] [Abstract][Full Text] [Related]
7. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D
J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
[TBL] [Abstract][Full Text] [Related]
8. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
10. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Margot NA; Waters JM; Miller MD
Antimicrob Agents Chemother; 2006 Dec; 50(12):4087-95. PubMed ID: 16982781
[TBL] [Abstract][Full Text] [Related]
11. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
Antivir Ther; 2002 Mar; 7(1):11-20. PubMed ID: 12008783
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
Opravil M; Hirschel B; Lazzarin A; Furrer H; Chave JP; Yerly S; Bisset LR; Fischer M; Vernazza P; Bernasconi E; Battegay M; Ledergerber B; Günthard H; Howe C; Weber R; Perrin L;
J Infect Dis; 2002 May; 185(9):1251-60. PubMed ID: 12001042
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
14. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
[TBL] [Abstract][Full Text] [Related]
15. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
Green H; Gibb DM; Walker AS; Pillay D; Butler K; Candeias F; Castelli-Gattinara G; Compagnucci A; Della Negra M; de Rossi A; Feiterna-Sperling C; Giaquinto C; Harper L; Levy J; Saidi Y; Wintergerst U;
AIDS; 2007 May; 21(8):947-55. PubMed ID: 17457088
[TBL] [Abstract][Full Text] [Related]
18. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
[TBL] [Abstract][Full Text] [Related]
20. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]